Local/Regional and Systemic Treatments of Hepatocellular Carcinoma

ABSTRACT

Screening programs for patients with cirrhosis are designed to detect hepatocellular carcinoma at an early stage when effective treatment is feasible and may provide long-term survival benefits. However, only a minority of these patients will be considered candidates for liver transplantation or surgical resection and hence, most cases will be evaluated for other medical options.

While systemic therapy has never been shown to bear a relevant antitumoral activity with an impact on survival, there are several locoregional options that can achieve a high rate of objective responses (this includes complete necrosis or partial reduction in tumor burden). Percutaneous ablation by any of the available methods (ethanol injection, radiofrequency, microwave, acetic acid injection, laser) is extremely useful in patients with small solitary tumors. Results indicate that 90% of tumors < 2 cm will be completely ablated using the percutaneous approach. However, when tumor size exceeds 3 cm and/or the number of nodules is greater than 3, the rate of treatment success is significantly reduced. In patients with large/multifocal disease, the sole option that has been shown to provide treatment efficacy with moderate improvement in survival is chemoembolization.

New therapeutic agents should target biological mechanisms in a tailored strategy, and the demonstration of beneficial results for patients should be obtained by large, randomized, controled trials comparing active intervention versus no treatment.

Hepatocellular carcinoma - treatment - chemoembolization - percutaneous ablation

REFERENCES

• 1 Bruix J, Sherman M, Llovet J M et al.. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.  J Hepatol. 2001;  35 421-430
• 2 Trinchet J C, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis.  J Hepatol. 1997;  27 756-765
• 3 Di Stasi M, Buscarini L, Livraghi T et al.. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates.  Scand J Gastroenterol. 1997;  32 1168-1173
• 4 Livraghi T, Giorgio A, Marin G et al.. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.  Radiology. 1995;  197 101-108
• 5 Ishii H, Okada S, Okusaka T et al.. Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection.  Cancer. 1998;  82 1638-1642
• 6 Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma.  Hepatology. 1992;  16 353-357
• 7 Shiina S, Tagawa K, Niwa Y et al.. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients.  AJR Am J Roentgenol. 1993;  160 1023-1028
• 8 Hasegawa S, Yamasaki N, Hiwaki T et al.. Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection.  Cancer. 1999;  86 1682-1690
• 9 Khan K N, Yatsuhashi H, Yamasaki K et al.. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection.  J Hepatol. 2000;  32 269-278
• 10 Lencioni R, Della Pina C, Bartolozzi C. Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma.  Abdom Imaging. 2005;  , In press
• 11 Sala M, Llovet J M, Vilana R et al.. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.  Hepatology. 2004;  40 1352-1360
• 12 Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation.  Gastroenterology. 2004;  127 S159-S166
• 13 Teratani T, Ishikawa T, Shiratori Y et al.. Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy.  Cancer. 2002;  95 816-823
• 14 Livraghi T, Benedini V, Lazzaroni S, Meloni F, Torzilli G, Vettori C. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma.  Cancer. 1998;  83 48-57
• 15 Ohnishi K. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma.  Hepatogastroenterology. 1998;  45(suppl 3) 1254-1258
• 16 Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results.  Eur Radiol. 2001;  11 914-921
• 17 Giorgio A, Tarantino L, de Stefano G et al.. Percutaneous sonographically guided saline-enhanced radiofrequency ablation of hepatocellular carcinoma.  AJR Am J Roentgenol. 2003;  181 479-484
• 18 Rhim H. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow: comparison with standard percutaneous radiofrequency ablation therapy.  Cancer. 2003;  98 433-435
• 19 Livraghi T, Meloni F. Treatment of hepatocellular carcinoma by percutaneous interventional methods.  Hepatogastroenterology. 2002;  49 62-71
• 20 Meloni M F, Goldberg S N, Moser V, Piazza G, Livraghi T. Colonic perforation and abscess following radiofrequency ablation treatment of hepatoma.  Eur J Ultrasound. 2002;  15 73-76
• 21 Tateishi R, Shiina S, Teratani T et al.. Percutaneous radiofrequency ablation for hepatocellular carcinoma.  Cancer. 2005;  103 1201-1209
• 22 Livraghi T, Goldberg S N, Lazzaroni S et al.. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.  Radiology. 2000;  214 761-768
• 23 Lin S M, Lin C J, Lin C C, Hsu C W, Chen Y C. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm.  Gastroenterology. 2004;  127 1714-1723
• 24 Lencioni R A, Allgaier H P, Cioni D et al.. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.  Radiology. 2003;  228 235-240
• 25 Seki T, Wakabayashi M, Nakagawa T et al.. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy.  Cancer. 1999;  85 1694-1702
• 26 Horigome H, Nomura T, Saso K, Itoh M. Standards for selecting percutaneous ethanol injection therapy or percutaneous microwave coagulation therapy for solitary small hepatocellular carcinoma: consideration of local recurrence.  Am J Gastroenterol. 1999;  94 1914-1917
• 27 Shibata T, Iimuro Y, Yamamoto Y et al.. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy.  Radiology. 2002;  223 331-337
• 28 Liang P, Dong B, Yu X et al.. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation.  Radiology. 2005;  235 299-307
• 29 Vogl T J, Straub R, Eichler K, Woitaschek D, Mack M G. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions).  Radiology. 2002;  225 367-377
• 30 Pacella C M, Bizzarri G, Magnolfi F et al.. Laser thermal ablation in the treatment of small hepatocellular carcinoma: results in 74 patients.  Radiology. 2001;  221 712-720
• 31 Zhou X D, Tang Z Y. Cryotherapy for primary liver cancer.  Semin Surg Oncol. 1998;  14 171-174
• 32 Seifert J K, Morris D L. World survey on the complications of hepatic and prostate cryotherapy.  World J Surg. 1999;  23 109-114
• 33 Seror O, N’Kontchou G, Haddar D et al.. Large infiltrative hepatocellular carcinomas: treatment with percutaneous intraarterial ethanol injection alone or in combination with conventional percutaneous ethanol injection.  Radiology. 2005;  234 299-309
• 34 Tacke J, Mahnken A, Roggan A, Gunther R W. Multipolar radiofrequency ablation: first clinical results.  Rofo. 2004;  176 324-329
• 35 Mahnken A H, Buecker A, Spuentrup E et al.. MR-guided radiofrequency ablation of hepatic malignancies at 1.5 T: initial results.  J Magn Reson Imaging. 2004;  19 342-348
• 36 Trinchet J C, Ganne-Carrie N, Beaugrand M. Review article: intra-arterial treatments in patients with hepatocellular carcinoma.  Aliment Pharmacol Ther. 2003;  17(suppl 2) 111-118
• 37 Takayasu K, Shima Y, Muramatsu Y et al.. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents.  Radiology. 1987;  163 345-351
• 38 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma . Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.  N Engl J Med. 1995;  332 1256-1261
• 39 Llovet J M, Real M I, Montana X et al.. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.  Lancet. 2002;  359 1734-1739
• 40 Pelletier G, Roche A, Ink O et al.. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.  J Hepatol. 1990;  11 181-184
• 41 Kasugai H, Kojima J, Tatsuta M et al.. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil.  Gastroenterology. 1989;  97 965-971
• 42 Pelletier G, Ducreux M, Gay F et al.. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.  J Hepatol. 1998;  29 129-134
• 43 Lo C M, Ngan H, Tso W K et al.. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.  Hepatology. 2002;  35 1164-1171
• 44 Bruix J, Llovet J M, Castells A et al.. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.  Hepatology. 1998;  27 1578-1583
• 45 Raoul J L, Guyader D, Bretagne J F et al.. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.  J Nucl Med. 1994;  35 1782-1787
• 46 Raoul J L, Guyader D, Bretagne J F et al.. Prospective randomized trial of chemoembolization versus intra-arterial injection of ¹³¹I-labeled-iodized oil in the treatment of hepatocellular carcinoma.  Hepatology. 1997;  26 1156-1161
• 47 Llovet J M, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival.  Hepatology. 2003;  37 429-442
• 48 Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum.  Lancet Oncol. 2004;  5 409-418
• 49 Mathurin P, Rixe O, Carbonell N et al.. Review article: overview of medical treatments in unresectable hepatocellular carcinoma-an impossible meta-analysis?.  Aliment Pharmacol Ther. 1998;  12 111-126
• 50 Farinati F, Salvagnini M, de Maria N et al.. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen.  J Hepatol. 1990;  11 297-301
• 51 Martinez Cerezo F J, Tomas A, Donoso L et al.. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma.  J Hepatol. 1994;  20 702-706
• 52 Chow P K, Tai B C, Tan C K et al.. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial.  Hepatology. 2002;  36 1221-1226
• 53 Castells A, Bruix J, Bru C et al.. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients.  Gastroenterology. 1995;  109 917-922
• 54 Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme).  Lancet. 1998;  352 17-20
• 55 Liu C L, Fan S T, Ng I O, Lo C M, Poon R T, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.  Am J Gastroenterol. 2000;  95 218-222
• 56 Madden M V, Krige J E, Bailey S et al.. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma.  Gut. 1993;  34 1598-1600
• 57 Chang J M, Tzeng W S, Pan H B, Yang C F, Lai K H. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study.  Cancer. 1994;  74 2449-2453
• 58 Koda M, Murawaki Y, Mitsuda A et al.. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study.  Cancer. 2001;  92 1516-1524
• 59 Riestra S, Rodriguez M, Delgado M et al.. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.  J Clin Gastroenterol. 1998;  26 200-203
• 60 Simonetti R G, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials.  Ann Oncol. 1997;  8 117-136
• 61 Villa E, Ferretti I, Grottola A et al.. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors.  Br J Cancer. 2001;  84 881-885
• 62 Grimaldi C, Bleiberg H, Gay F et al.. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial.  J Clin Oncol. 1998;  16 411-417
• 63 Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire . Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated by tamoxifen.  Hepatology. 2004;  40 1361-1369
• 64 Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos O N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.  Gut. 1998;  42 442-447
• 65 Yuen M F, Poon R T, Lai C L et al.. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.  Hepatology. 2002;  36 687-691
• 66 Lai C L, Lau J Y, Wu P C et al.. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.  Hepatology. 1993;  17 389-394
• 67 Llovet J M, Sala M, Castells L et al.. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.  Hepatology. 2000;  31 54-58
• 68 Kawata S, Yamasaki E, Nagase T et al.. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.  Br J Cancer. 2001;  84 886-891
• 69 Livraghi T, Solbiati L, Meloni M F et al.. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.  Radiology. 2003;  226 441-451